News @ Qprotyn

Changing the world, one mAb at a time.

We are always pushing the frontier of technology’s impact in the world of biologics. We feel that modern technology allows easy crossover of ideas across borders and cultures. Our achievements and our knowledge are to be shared with the community and the technology ecosystem.

Ocular diseases and the rise of Biologics in the field of Ophthalmology

Janak Vadgama

Dec 7, 2021
2 min

Ocular diseases and the rise of Biologics in the field of Ophthalmology

Speaking at the American Academy of Optometry 2021 annual meeting in Boston, Anthony DeWilde, OD, FAAO, discussed biologics, which hold...

19 views0 comments

Qprotyn achieves viscosity of 18cP for 250mg/mL of Trastuzumab using its HILOPRO technology.

Janak Vadgama

Sep 3, 2021
2 min

Qprotyn achieves viscosity of 18cP for 250mg/mL of Trastuzumab using its HILOPRO technology.

Upgrading Trastuzumab from IV to Subcutaneous (SubQ) administration may now be possible without expensive, high-volume hyaluronidase...

50 views

Qprotyn achieves viscosity of 14 cP for 250mg/mL of Bevacizumab using its HILOPRO technology.

Janak Vadgama

Aug 5, 2021
2 min

Qprotyn achieves viscosity of 14 cP for 250mg/mL of Bevacizumab using its HILOPRO technology.

Upgrading Bevacizumab from IV to subcutaneous (SubQ) administration may now be possible with Qprotyn's HILOPRO technology Innovator...

27 views